Skip to main content

Abaloparatide Real-World Patient Experience Study.

Publication ,  Journal Article
Gold, DT; Weiss, R; Beckett, T; Deal, C; Epstein, RS; James, AL; Kernaghan, JM; Mohseni, M; Spiegel, M; Vokes, T; Roberts, J; Bailey, T ...
Published in: JBMR Plus
March 2021

Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection. Eight geographically diverse secondary care sites in the United States participated (n = 193). Mean ± SD age was 67.4 ±8.62 years. Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important. The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%). All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence. Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose. Although injecting medication (18%) and higher out-of-pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives. In multivariable analyses, ease of preparation (OR = 2.62; 95% CI, 1.01-6.81; p = 0.048) and fracture history (OR = 1.72; 95% CI, 1.03-2.86; p = 0.037) were significantly associated with overall satisfaction. Ease of preparation was a predictor of higher satisfaction with treatment convenience (coefficient = 13.60; 95% CI, 8.08-19.12; p = 0.00). Remembering to take the medication was a significant predictor of self-reported adherence (OR = 16.66; 95% CI, 3.30-84.24; p = 0.001). In conclusion, the majority of patients were satisfied with ABL and found it convenient/easy to prepare and store. High self-reported adherence may be associated with positive patient experience including ease of use and adequate support from healthcare providers. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JBMR Plus

DOI

EISSN

2473-4039

Publication Date

March 2021

Volume

5

Issue

3

Start / End Page

e10457

Location

England

Related Subject Headings

  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gold, D. T., Weiss, R., Beckett, T., Deal, C., Epstein, R. S., James, A. L., … Williams, S. A. (2021). Abaloparatide Real-World Patient Experience Study. JBMR Plus, 5(3), e10457. https://doi.org/10.1002/jbm4.10457
Gold, Deborah T., Richard Weiss, Tammy Beckett, Chad Deal, Robert S. Epstein, Andrew L. James, Jacqueline M. Kernaghan, et al. “Abaloparatide Real-World Patient Experience Study.JBMR Plus 5, no. 3 (March 2021): e10457. https://doi.org/10.1002/jbm4.10457.
Gold DT, Weiss R, Beckett T, Deal C, Epstein RS, James AL, et al. Abaloparatide Real-World Patient Experience Study. JBMR Plus. 2021 Mar;5(3):e10457.
Gold, Deborah T., et al. “Abaloparatide Real-World Patient Experience Study.JBMR Plus, vol. 5, no. 3, Mar. 2021, p. e10457. Pubmed, doi:10.1002/jbm4.10457.
Gold DT, Weiss R, Beckett T, Deal C, Epstein RS, James AL, Kernaghan JM, Mohseni M, Spiegel M, Vokes T, Roberts J, Bailey T, Wang Y, Williams SA. Abaloparatide Real-World Patient Experience Study. JBMR Plus. 2021 Mar;5(3):e10457.

Published In

JBMR Plus

DOI

EISSN

2473-4039

Publication Date

March 2021

Volume

5

Issue

3

Start / End Page

e10457

Location

England

Related Subject Headings

  • 32 Biomedical and clinical sciences